Glioblastoma

The supplied grounding supports a molecularly complex disease rather than a single cause. Review abstracts emphasize genetic and epigenetic alterations, including IDH-wildtype biology, DNA methylation changes, and genomic reprogramming, but do not identify one definitive aetiology. No specific environmental or inherited cause is supported in the grounding.

Glioblastoma is characterized by aggressive tumor growth, marked cellular atypia, necrosis, and prominent angiogenesis. The literature grounding also describes a highly immunosuppressive tumor microenvironment, tumor heterogeneity, resistance-associated stem-like cells, and involvement of developmental pathways, DNA damage response, metabolism, and signal transduction. These features contribute to recurrence and therapeutic resistance.

The grounding supports adult age at presentation, most often in the fifth or sixth decade of life. It also indicates that glioblastoma is the most common malignant primary brain tumor in adults and is discussed as IDH-wildtype in current management reviews, but it does not provide additional validated risk factors. No other risk factors are supported by the supplied material.

Current standard management is feasible surgical resection followed by radiotherapy plus temozolomide chemotherapy. The supplied reviews also discuss targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, viral therapies, and anti-angiogenesis approaches as emerging or investigational modalities. Bevacizumab and immune checkpoint blockade are among the co-studied treatment-related entities, but the grounding does not support them as universal standard therapy.